Failing Surgical Bioprosthesis: A Challenge on the Rise

Courtesy of Dr. Carlos Fava.

The gold standard for failing aortic bioprosthesis has traditionally been surgery. However, since the first valve in valve (TAV-in-SAV) report in 2007, by Wenaweser, transcatheter valve implantation has emerged as a valid alternative. Even so, at present there is not enough scientific evidence in this regard.

Degeneración de las válvulas biológicas aórticas: un desafío cada vez más frecuente

The present study analyzed 205 patients presenting failing aortic bioprosthesis. 126 (61.5%) were reoperated (redo-SAVR) and 798 received TAV-in-SAV.


Read also: How Is Renal Function Affected by Endoprosthesis Implantation?”


Those receiving TAV-in-SAV were older, had more comorbidities, more cardiac failure and had higher STS and EurosSCORElog. After propensity score matching, the sample population was homogenized to 78 pares.

 

Mortality at 30 days and one year was numerically inferior in the TAV-in-SAV group, though it had no statistical significance (6.4% vs. 3.9% and 13.1% vs. 12.3%). Neither were there differences in stroke, AMI or need for definite pacemaker. The need for dialysis driven by acute kidney failure was numerically lower in the TAV-in-SAV group (11.5% vs. 3.8% p=0.13). Outcomes were similar across the population.

 

Hospitalization was lower in the TAV-in-SAV group (p=0.001).


Read also: TAVR in Patients with Pure vs. Mixed Aortic Stenosis: Benefits and Evolution”.


Gradients at 30 days were higher in the TAV-in-SAV group (18.1 mmHg vs. 14.3 mmHg p=0.01). This was at the expense of the Edwards valves (21.3 mmHg gradient), not with the CoreValves (15.4 mmHg) that showed no difference with redo-SAVR. The presence of >20 mmHg gradient was twice as high with the Edwards compared against the CoreValve and redo-SAVR (51.9% vs. 22.6% and 17.1%).

 

Conclusion

Patients presenting failing aortic bioprosthesis due to severe aortic stenosis treated with redo-SAVR or TAV-in-SAV have similar evolution at 30 days and one year.

 

Commentary

This group currently presents a great challenge and is being researched at the moment.

 

This retrospective study showed similar evolution in both groups, but with less hospitalization days in the TAV-in-SAV. However, a nine-day hospital stay is still high.

 

It is important to choose the right transcatheter valve, since one of these presented higher post-implantation gradients. This will certainly improve with experience and the development of new devices.

 

Gentileza del Dr. Carlos Fava.

 

Original title: Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses. A multicenter propensity score analysis.

Reference: Marco Spaziano, et al. EuroIntervention 2017;13:1149-1156.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...